加载中
NASDAQHealthcareBiotechnology
最新数据
US$26.85
−US$0.63 · -2.29%
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
收盘时
US$26.85
−US$0.63 · -2.29%
盘后
US$27.13
+US$0.28 · +1.04%
10月13日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
日内区间
当前US$26.85
52周区间
当前US$26.85
盘中时间采用ET。市场数据可能有所延迟。
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
日内区间
当前US$26.85
52周区间
当前US$26.85
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 8737.1万 USD | 3.81亿 USD | 2223万 USD | — |
| 销货成本 | 52.5万 USD | 4215.6万 USD | 2544.1万 USD | 299.3万 USD | — |
| 毛利 | −52.5万 USD | 4521.5万 USD | 3.55亿 USD | 1923.7万 USD | — |
| 研究与开发 | 9040.4万 USD | 1.04亿 USD | 1.28亿 USD | 9345万 USD | 4404万 USD |
| 销售、一般及管理费用 | 6288.7万 USD | 1.14亿 USD | 1.88亿 USD | 1.27亿 USD | 3893.3万 USD |
| 营业费用 | 1.53亿 USD | 3.6亿 USD | 3.17亿 USD | 2.21亿 USD | 8268.8万 USD |
| 利息收入 | 930.2万 USD | 1380.9万 USD | 1615.5万 USD | 429.1万 USD | 3.6万 USD |
| 折旧和摊销 | 52.5万 USD | 90.4万 USD | 108.8万 USD | 48.7万 USD | 5.2万 USD |
| 营业利润 | −1.53亿 USD | −3.15亿 USD | 3880.2万 USD | −2.01亿 USD | −8268.8万 USD |
| 净利润 | −1.45亿 USD | −3.02亿 USD | 4927.1万 USD | −1.98亿 USD | −8793.1万 USD |
公司数据更新于 2026年10月14日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.28亿0.01%2.3万亿 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM7331.4万0.10%787.4亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF3881.11万0.04%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO2627.14万0.19%139.17亿 USD0.24%US$351.1-0.74%
iShares Biotechnology ETFIBB2275.21万0.21%108.2亿 USD0.44%US$200.02-2.08%
Vanguard Russell 2000 ETFVTWO2010.11万0.11%180亿 USD0.06%US$111.77-0.45%
Schwab U.S. Small-Cap ETFSCHA1489.97万0.07%217.13亿 USD0.03%US$32.56-0.31%
iShares U.S. Pharmaceuticals ETFIHE981.27万0.63%15.53亿 USD0.37%US$97.36-2.82%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
